Infertility News and Research

RSS

Infertility primarily refers to the biological inability of a person to contribute to conception. Infertility may also refer to the state of a woman who is unable to carry a pregnancy to full term.

Educational video induces girls diagnosed with PID to ensure partner treatment

A study at Johns Hopkins Children's Center found that girls diagnosed with pelvic inflammatory disease (PID) who watched a short educational video were three times more likely to discuss their condition with their partners and to ensure partner treatment than girls diagnosed and treated without seeing the film.

5 Nov 2009

Majority of women smokers unaware of immediate and long term health risks

Many women are aware that smoking can lead to lung cancer, heart disease and premature death. But a recent survey conducted by Angus Reid on behalf of nicotine replacement therapy brands, NICODERM(R) and NICORETTE(R) reveals that the majority of Canadian women who smoke are not necessarily aware of the host of other impacts that smoking can have on their immediate and longer term health.

4 Nov 2009

Comparative study reveals similar brain networks in human and monkey brains

A study published this week in PNAS provides a comprehensive comparative functional anatomy study in human and monkey brains which reveals highly similar brain networks preserved across evolution.

4 Nov 2009

Vitrolife takes over sales and marketing management of fertility media in UK and Ireland

Vitrolife (STO:VITR) is taking over management of marketing and sales of fertility media in UK and Ireland. “The acquisition is in line with Vitrolife’s strategy to operate using our own personnel and our own management in the most important markets,” says Magnus Nilsson, Vitrolife’s CEO.

2 Nov 2009

NIEHS supports research to study the potential effects of BPA on human health

Researchers studying the health effects of the chemical bisphenol A (BPA) gathered in North Carolina to launch an integrated research initiative to produce data that will allow for a comprehensive assessment of its possible human health effects.

29 Oct 2009

Study shows 62.2 percent of women turn to alternative therapies before medical treatments for infertility

In a recent study from the Ohio State University Medical Center, 62.2 percent of those surveyed turned to alternative therapies before turning to more invasive medical treatments for infertility and getting pregnant.

29 Oct 2009

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Perhaps the most comprehensive, multi-institutional study yet of the sexually transmitted bacteria chlamydia is under way at the University of Maryland, Baltimore (UMB).

29 Oct 2009

Fertility Centers of Illinois offers "baby or money back" program

A new study has confirmed anecdotal reports that the recession has caused a decline in fertility treatments across the country. With price being the major deterrent, the report indicates that assisted reproductive technology (ART) such as In Vitro Fertilization (IVF) is sought mostly by affluent, educated, Caucasian women and forecasts a 5% decline in IVF procedures by the end of 2009.

28 Oct 2009

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com) and Reproductive Medicine Associates of New York (RMA of New York) have shown that immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived. Immature eggs are normally discarded during standard in vitro fertilization (IVF) procedures due to their inability to create an embryo.

28 Oct 2009

Clinical results of INVO procedure for treatment of infertility announced

INVO Bioscience announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure.

28 Oct 2009

Columbia Laboratories to raise funds through sale of its common stock and warrants

Columbia Laboratories, Inc. today announced that it has priced a transaction to raise up to approximately $11,772,000 through the sale of up to approximately 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.5 shares of common stock.

24 Oct 2009

Combination treatement for IVF patients may eliminate vaginal bleeding

A prospective, multi-center study demonstrated that in IVF (in vitro fertilization) cycles supplemented with once-daily dosing of Crinone® vaginal progesterone gel and Estrace® oral estrogen, vaginal bleeding is rare in patients who become pregnant. Bleeding does occur in approximately one-quarter of patients who do not become pregnant. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

23 Oct 2009

Researchers develop a non-invasive test to help assess embryo viability for IVF

Embryos that are most likely to result in a pregnancy are crucial to the success of in vitro fertilization (IVF) but are difficult to identify. Researchers at Yale School of Medicine, led by Emre Seli, M.D., are developing a fast, non-invasive test to help assess embryo viability for IVF.

22 Oct 2009

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.

21 Oct 2009

No significant differences in pregnancy outcomes with different progesterone formulations

A retrospective analysis, conducted at a large infertility clinic between January 2003 and December 2008, demonstrated that there were no significant differences in pregnancy outcomes with three different progesterone formulations for women aged 35 to 40 undergoing in vitro fertilization-embryo transfer (IVF-ET) procedures. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

21 Oct 2009

Complimentary book for fertility patients placing first fertility cycle order

Village Fertility Pharmacy (www.villagefertilitypharmacy.com), a specialty pharmacy focused exclusively on infertility medications, is pleased to announce that, effectively immediately, fertility patients who place a fertility cycle order for the first time will receive a complimentary copy of Kristen Magnacca's award-winning book, "Love and Infertility: Strategies for Survival - Balancing Infertility, Marriage, and Life."

20 Oct 2009

Rituxan drug effective for treating ANCA-associated vasculitis

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.

19 Oct 2009

Recently approved Gleevec drug for cancer treatment

Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual meeting of the American College of Rheumatology on October 18 in Philadelphia.

19 Oct 2009

Co-promotion agreement to promote Prosed DS to urologists and retail pharmacists

Timm Medical Technologies, Inc., a specialist Urology company, announced today its exclusive co-promotion agreement with Ferring Pharmaceuticals Inc., a Swiss-based biopharmaceutical company, for Prosed® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) in the United States.

15 Oct 2009

More than half RCTs do not report vital information about study populations race, says study

A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.

15 Oct 2009

Infertility News and Research

Further Reading

Educational video induces girls diagnosed with PID to ensure partner treatment

Majority of women smokers unaware of immediate and long term health risks

Comparative study reveals similar brain networks in human and monkey brains

Vitrolife takes over sales and marketing management of fertility media in UK and Ireland

NIEHS supports research to study the potential effects of BPA on human health

Study shows 62.2 percent of women turn to alternative therapies before medical treatments for infertility

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Fertility Centers of Illinois offers "baby or money back" program

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

Clinical results of INVO procedure for treatment of infertility announced

Columbia Laboratories to raise funds through sale of its common stock and warrants

Combination treatement for IVF patients may eliminate vaginal bleeding

Researchers develop a non-invasive test to help assess embryo viability for IVF

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

No significant differences in pregnancy outcomes with different progesterone formulations

Complimentary book for fertility patients placing first fertility cycle order

Rituxan drug effective for treating ANCA-associated vasculitis

Recently approved Gleevec drug for cancer treatment

Co-promotion agreement to promote Prosed DS to urologists and retail pharmacists

More than half RCTs do not report vital information about study populations race, says study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News